1 / 11

Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Ne

SARC 006. Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors. Brigitte Widemann, NCI, POB. SARC006 Study Objectives. Primary Objective Determine clinical response rate (WHO)

reece
Télécharger la présentation

Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Ne

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SARC 006 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Brigitte Widemann, NCI, POB

  2. SARC006 Study Objectives • Primary Objective • Determine clinical response rate (WHO) • High grade, unresectable, or metastatic, potentially resectable sporadic and NFI associated MPNST for which neoadjuvant chemotherapy is determined to be the best treatment option by institutional PI • Secondary Objectives • Imaging (PET/Volumetric MRI analysis) • Pathology (Percent necrosis; tissue microarray) • Biomarker • Improve knowledge of NF1 epidemiology

  3. Trial Schema *Eight chemotherapy courses total IA x2 IE x2 NF1 MPNST Local Control Response Evaluation Chemotherapy IA x 2 IE x2 Sporadic PET 3D MRI Surgery XRT PET 3D MRI MRI

  4. Patient Eligibility • Sporadic or NF1 associated MPNST • Unresectable; metastatic; potentially resectable but neoadjuvant chemotherapy is determined to be in the best patient interest • Not previously treated with chemotherapy; prior radiation permitted • No upper or lower age limit • ECOG 0-2 • Normal organ function • Cardiac (MUGA or Echo) • Renal, liver and bone marrow • Prior treatment with biologic agents or chemotherapy for other NF1 associated tumors permitted • No prior ifosfamide, etoposide or doxorubicin

  5. Trial Status • Patients enrolled: 12 • NF1 associated MPNST 8 pts; sporadic MPNST 3 pts • Median age 29.5 years (range 21-67 years) • Disease status: • Localized 7 pts; metastatic: 5 pts • On study 7 pts, off study 5 pts • SAEs (possibly, probably, or definitely related): • One pt: Ifosfamide related aphasia (gr. 4), somnolence (gr. 4) • One pt: Anemia, dyspnea, and fatigue (gr. 3), orthostatic hypotension (gr. 2) • One pt: Urinary tract infection (gr. 3) • One pt: Leukopenia (gr. 4) and fever (gr. 1)

  6. Response Evaluation NF1 MPNST Nine patients enrolled

  7. Response Evaluation Sporadic MPNST Three patients enrolled

  8. SARC 006 Protocol Status • SARC Sites:

  9. SARC 006 Protocol Status • SARC Sites: • Not participating: City of Hope, Dana-Farber, Fox Chase, Johns Hopkins, Moffitt, MSKCC, Oregon Health and Science University, Sarcoma Oncology Center, Stanford, Seattle Care Alliance, UCLA, University of Florida, Washington Cancer Institute

  10. SARC 006 Protocol Status • NF1 Sites:

  11. SARC 006 Approval Process • Contract with SARC • Institutional protocol review • US Army IRB review: • Informed consent form, assent (ages 13-17 years) form, and information page (ages 7-12 years old), site specific protocol appendices • CV for all investigators • Facility safety plan • PI assurance plan • GCP training for PI • US Army will perform pre-review of documents prior to local IRB submission • All communication with US Army IRB through SARC

More Related